MacroGenics, Inc. (NASDAQ:MGNX) has received a consensus recommendation of “Hold” from the fifteen analysts that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $31.56.

A number of equities analysts have weighed in on MGNX shares. Cowen and Company reiterated a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $26.00 price objective on shares of MacroGenics in a research note on Friday, September 1st. Zacks Investment Research lowered MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Wedbush reiterated an “outperform” rating and set a $44.00 price objective on shares of MacroGenics in a research note on Monday, September 11th. Finally, ValuEngine upgraded MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

MacroGenics (NASDAQ MGNX) traded down 1.26% during mid-day trading on Wednesday, reaching $19.54. The company had a trading volume of 160,118 shares. MacroGenics has a 52 week low of $14.36 and a 52 week high of $31.85. The stock’s 50-day moving average price is $17.78 and its 200 day moving average price is $18.18. The firm’s market capitalization is $719.03 million.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.09). The firm had revenue of $1.70 million for the quarter, compared to analyst estimates of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The business’s revenue was down 97.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.12 EPS. On average, equities research analysts predict that MacroGenics will post ($4.41) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “MacroGenics, Inc. (MGNX) Given Average Recommendation of “Hold” by Brokerages” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/01/macrogenics-inc-mgnx-given-average-recommendation-of-hold-by-brokerages.html.

In other news, SVP Jon Marc Wigginton sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 25th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the transaction, the senior vice president now directly owns 40,000 shares in the company, valued at approximately $800,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 8.30% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in MacroGenics in the second quarter valued at approximately $133,000. Legal & General Group Plc lifted its holdings in MacroGenics by 4.3% in the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 328 shares during the last quarter. SG Americas Securities LLC lifted its holdings in MacroGenics by 92.2% in the second quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 5,187 shares during the last quarter. Parametric Portfolio Associates LLC acquired a new position in MacroGenics in the second quarter valued at approximately $203,000. Finally, Virtu KCG Holdings LLC acquired a new position in MacroGenics in the second quarter valued at approximately $232,000. Institutional investors and hedge funds own 84.63% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.